FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Ursula Vehling‐Kaiser et al.|The Lancet Oncology|2014Cited by 1.7k
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).Volker Heinemann, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al.|Journal of Clinical Oncology|2013Cited by 102